Measured in a cytotoxicity assay using L-929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is typically 2-20 pg/mL.

TNF alpha Protein, Cynomolgus, Rhesus, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.4 kDa and the accession number is NP_001040614.1.

Cynomolgus,Rhesus

E. coli

tumor necrosis factor,TNF-α

A DNA sequence encoding the cynomolgus / rhesus TNF [(Identical to the rhesus TNF (NP_001040614.1)] (Val77-Leu233) was expressed and purified with an initial Met. Cynomolgus and Rhesus TNF sequences are identical. Predicted N terminal: Met

> 90 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Tumor necrosis factor alpha (TNF-alpha), also known as TNF, TNFA or TNFSF2, is the prototypic cytokine of the TNF superfamily, and is a multifunctional molecule involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. Two receptors, TNF-R1 (TNF receptor type 1; CD120a; p55/60) and TNF-R2 (TNF receptor type 2; CD120b; p75/80), bind to TNF-alpha. TNF-alpha protein is produced mainly by macrophages, and large amounts of this cytokine are released in response to lipopolysaccharide, other bacterial products, and Interleukin-1 (IL-1). TNF-alpha is involved in fighting against the tumorigenesis, thus, is regarded as a molecular insight in cancer treatment.TNF-alpha Protein & AntibodyCancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy